Precardia, Inc.

Acute decompensated heart failure (ADHF) is a leading cause of morbidity and mortality worldwide. In the US alone, ADHF is responsible for over 1 million hospitalizations per year, making it a significant driver of healthcare costs. The clinical syndrome is characterized by the development of dyspnea, often associated with the accumulation of fluid within the lung's interstitial and alveolar spaces (resulting from acutely elevated cardiac filling pressures). Hallmark features such as pulmonary edema are terrifying, painful experiences that patients invariably describe as "drowning". Despite currently available treatments, ADHF remains associated with a poor quality of life and high mortality. There exists no pharmaceutical path to arresting or reversing heart failure, and current approaches (associated with significant systemic side-effects) are only available as palliatives to reduce the symptoms. preCARDIA is dedicated to improving patients' quality of life through pioneering clinically advanced technology that offers an alternative solution for physicians and their patients suffering from ADHF. preCARDIA's current technology, a proprietary balloon catheter and pump controller is designed to address ADHF via intermittent superior vena cava (SVC) occlusion. By limiting venous return to the heart, preCARDIA treats fundamental ADHF clinical hemodynamic targets. The company was founded & incubated by MD Start. PreCardia was acquired by Abiomed in 2021 (www.abiomed.com) The preCARDIA System is an investigational device and is limited by Federal (or United States) Law to investigational use.

• Employees 3
• Founded 2017